MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address serious unmet medical needs, today announced the pricing of its upsized initial public offering of 21,177,600 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Eikon has granted the underwriters a 30-day option to purchase up to an additional 3,176,640 shares of ...